Nuvalent (NUVL) Return on Capital Employed (2021 - 2026)
Nuvalent's (NUVL) quarterly Return on Capital Employed came in at 34.0% in Q1 2026, down 324.0% YoY from 15.18% in Q1 2025, and up 9.31% on a QoQ basis from 37.49% in Q4 2025.
Nuvalent (NUVL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Nuvalent (NUVL) has 6 years of Return on Capital Employed data on file, last reported at 34.0% in Q1 2026.
- Quarterly Return on Capital Employed fell 324.0% year-over-year to 34.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.0% (down 324.0% YoY) and the FY2025 annual result came in at 34.93%, down 318.0% from the prior year.
- Return on Capital Employed advanced to 34.0% in Q1 2026, from 37.49% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.68% in Q1 2022 to a low of 43.25% in Q3 2025.
- A 5-year average of 29.42% and a median of 27.33% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 543 bps — and 2025, when it tumbled 1595 bps.
- Tracing NUVL's Return on Capital Employed over 5 years: stood at 24.85% in 2022, then retreated by 10 bps to 27.33% in 2023, then grew by 8 bps to 25.23% in 2024, then sank by 49 bps to 37.49% in 2025, then rose by 9 bps to 34.0% in 2026.
- The last three Return on Capital Employed figures came in at 34.0% (Q1 2026), 37.49% (Q4 2025), and 43.25% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -34.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.00% |
| Dec 31, 2025 | -37.49% |
| Sep 30, 2025 | -43.25% |
| Jun 30, 2025 | -36.27% |
| Mar 31, 2025 | -30.76% |
| Dec 31, 2024 | -25.23% |
| Sep 30, 2024 | -27.30% |
| Jun 30, 2024 | -31.05% |
| Mar 31, 2024 | -25.02% |
| Dec 31, 2023 | -27.33% |
| Sep 30, 2023 | -32.73% |
| Jun 30, 2023 | -26.46% |
| Mar 31, 2023 | -21.69% |
| Dec 31, 2022 | -24.85% |
| Sep 30, 2022 | -30.49% |
| Jun 30, 2022 | -25.47% |
| Mar 31, 2022 | -20.68% |
| Dec 31, 2021 | -15.68% |
| Sep 30, 2021 | -15.37% |